Trade-Ideas LLC identified

Stryker

(

SYK

) as a new lifetime high candidate. In addition to specific proprietary factors, Trade-Ideas identified Stryker as such a stock due to the following factors:

  • SYK has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $203.8 million.
  • SYK has traded 20,616 shares today.
  • SYK is trading at a new lifetime high.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in SYK with the Ticky from Trade-Ideas. See the FREE profile for SYK NOW at Trade-Ideas

More details on SYK:

Stryker Corporation, together with its subsidiaries, operates as a medical technology company. It operates through three segments: Orthopaedics; MedSurg; and Neurotechnology and Spine. The stock currently has a dividend yield of 1.3%. SYK has a PE ratio of 63. Currently there are 16 analysts that rate Stryker a buy, 2 analysts rate it a sell, and 6 rate it a hold.

The average volume for Stryker has been 1.4 million shares per day over the past 30 days. Stryker has a market cap of $42.9 billion and is part of the health care sector and health services industry. The stock has a beta of 0.76 and a short float of 2.2% with 4.77 days to cover. Shares are up 24.8% year-to-date as of the close of trading on Tuesday.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

TheStreetRatings.com

Analysis:

TheStreet Quant Ratings

rates Stryker as a

buy

. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, compelling growth in net income, revenue growth and notable return on equity. We feel its strengths outweigh the fact that the company shows weak operating cash flow.

Highlights from the ratings report include:

  • Looking at where the stock is today compared to one year ago, we find that it is not only higher, but it has also clearly outperformed the rise in the S&P 500 over the same period. Although other factors naturally played a role, the company's strong earnings growth was key. Looking ahead, unless broad bear market conditions prevail, we still see more upside potential for this stock, despite the fact that it has already risen over the past year.
  • STRYKER CORP reported significant earnings per share improvement in the most recent quarter compared to the same quarter a year ago. The company has demonstrated a pattern of positive earnings per share growth over the past two years. We feel that this trend should continue. During the past fiscal year, STRYKER CORP increased its bottom line by earning $3.78 versus $1.34 in the prior year. This year, the market expects an improvement in earnings ($5.75 versus $3.78).
  • The company, on the basis of net income growth from the same quarter one year ago, has significantly outperformed against the S&P 500 and exceeded that of the Health Care Equipment & Supplies industry average. The net income increased by 79.5% when compared to the same quarter one year prior, rising from $224.00 million to $402.00 million.
  • Despite its growing revenue, the company underperformed as compared with the industry average of 6.9%. Since the same quarter one year prior, revenues slightly increased by 4.9%. Growth in the company's revenue appears to have helped boost the earnings per share.
  • The company's current return on equity greatly increased when compared to its ROE from the same quarter one year prior. This is a signal of significant strength within the corporation. Compared to other companies in the Health Care Equipment & Supplies industry and the overall market, STRYKER CORP's return on equity exceeds that of both the industry average and the S&P 500.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.